SecBot SecBot
8-K ·Filed Aug 11, 2026

CAH

CARDINAL HEALTH INC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000721371-26-000037
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q4 beat combined with FY2027 guidance above the long-term target and a massive $5.0B buyback authorization creates a powerful catalyst. Traders should watch for upward analyst revisions and potential multiple expansion as the market prices in sustained double-digit EPS growth. The Kroger contract renewal removes a key overhang.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$240.26
T+0 close · Aug 11, 2026 · via day close
Latest settled
+9.02%
T+60 · $261.93
Vs SPY
+9.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $240.26entry
  2. T+1 · 3mo ago −2.54%α −2.79% · $234.16
  3. T+5 · 3mo ago −2.20%α −1.79% · $234.98
  4. T+20 · 2mo ago −0.14%α +0.92% · $239.92
  5. T+60 · 13d ago +9.02%α +9.51% · $261.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cardinal Health reported strong Q4 FY2026 results with revenue of $63.7B (+6% YoY) and GAAP EPS of $1.70 (+70% YoY). Non-GAAP EPS of $2.91 (+40% YoY) included a $0.31 one-time benefit from IEEPA tariff refunds; excluding that, non-GAAP EPS grew 25% to $2.60. The company provided FY2027 non-GAAP EPS guidance of $12.40-$12.60 (+13-15% growth), above its long-term target, and announced a $5.0B incremental share repurchase authorization. The combination of a strong Q4 beat, raised FY2027 guidance above consensus, and a massive capital return program is a clear bullish signal for the stock.

Key Financial Metrics

EPS
$2.91
est $2.42 · +20.3%
Revenue
$63.7B
est $65.1B · -2.2% · +5.8% YoY
Rating
strong beat
Free Cash Flow
$5.0B
Gross Margin
4.02%

Key Facts

  • Q4 FY2026 revenue $63.7B (+6% YoY), GAAP EPS $1.70 (+70% YoY), Non-GAAP EPS $2.91 (+40% YoY)
  • FY2027 non-GAAP EPS guidance $12.40-$12.60 (+13-15% growth), above long-term target
  • Board approved $5.0B incremental share repurchase authorization, total authorization now $6.4B
  • FY2026 operating cash flow $5.2B, adjusted free cash flow $5.0B
  • All five operating segments grew profit double-digits in FY2026
  • Pharmaceutical & Specialty Solutions segment profit +21% in Q4
  • GMPD segment profit $150M in Q4, driven by $100M IEEPA tariff refunds
  • Other segment (NPHS, at-Home, OptiFreight) profit +14% in Q4
  • Completed $1.4B in share repurchases in FY2026, including $350M incremental ASR
  • Long-term renewal of wholesaler distribution contract with Kroger

Financial Impact

FY2027 non-GAAP EPS guidance of $12.40-$12.60 represents 13-15% growth over adjusted FY2026 non-GAAP EPS of $10.95, above the company's long-term EPS growth target. $5.0B incremental buyback authorization signals strong capital return.

revenueepsguidanceshare repurchasesfree cash flow

Risk Factors

  • GMPD segment profit excluding IEEPA tariff refunds declined 29% in Q4, indicating underlying weakness
  • Tariff uncertainty remains a risk for the medical products segment
  • Interest expense increased 7% in Q4 and is guided higher for FY2027 ($240M-$290M)
  • Integration of recent acquisitions (Strive Medical, AdaptHealth diabetes business) carries execution risk

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000721371-26-000037
Document: cah-20260811.htm0000721371-26-000037
Document: 0000721371-26-000037-index-headers.html0000721371-26-000037
Document: 0000721371-26-000037-index.html0000721371-26-000037
Document: 0000721371-26-000037.txt0000721371-26-000037
8-K Data (Synthetic)0000721371-26-000037

Track record

17 reports on CAH

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 3 Neutral 2/10 Entry $283.50 Now $283.85 +0.12% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $283.35 Now $283.85 −0.18% settles Nov 23
  3. Nov 11, 20265d ago Press Release Neutral 2/10 Entry $278.14 Now $283.85 +2.05% settles Nov 19
  4. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $267.82 to $278.14 Now $283.85 +5.99% ▲ +3.85% +0.56% vs SPY
  5. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $251.09 to $267.82 Now $283.85 +13.05% ▲ +6.66% +11.39% vs SPY
  6. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $244.76 to $261.93 Now $283.85 +15.97% ▲ +7.01% +7.73% vs SPY
  7. Oct 27, 202621d ago GOVT-CONTRACT Neutral 4/10 Entry $244.76 to $261.93 Now $283.85 +15.97% ▲ +7.01% +7.73% vs SPY
  8. Oct 1, 20266w ago 8-K Neutral 5/10 Entry $230.09 to $238.96 Now $283.85 +23.36% ▲ +3.85% +2.55% vs SPY
  9. Oct 1, 20266w ago Press Release Neutral 1/10 Entry $230.09 to $238.96 Now $283.85 +23.36% ▲ +3.85% +2.55% vs SPY
  10. Aug 20, 202612w ago Insider Cluster Neutral 4/10 Entry $228.46 to $235.13 Now $283.85 +24.24% ▲ +2.92% +1.80% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026